Jin Han
Clinical Associate Professor, University of Illinois at Chicago
Contact
Address:
833 S. Wood Street Rm 164 (MC886), Chicago, IL
Email:
Related Sites:
About
Research Interests:
Pain management, sickle cell disease (SCD), safety and effectiveness of agents used in SCD, evaluation of clinical pharmacy services and interventions, and pharmacogenomics.
Teaching and Supervision
PDAT 9: Hematology/Oncology (PHAR 41631), 1/12/2026 – 5/1/2026
PDAT 9: Hematology/Oncology (PHAR 41628), 1/12/2026 – 5/1/2026
Pharmacokinetics (PHAR 435), 8/31/2025 – 12/31/2025
Pharmacokinetics (PHAR 435), 8/31/2025 – 12/31/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/26/2024 – 12/6/2024
Selected Grants
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors", National Institutes of Health (National Heart, Lung, and Blood Institute)., 9/15/2025 - 6/30/2030, Obligated Amount: $755853; Anticipated Amount: $3781729
CTA: An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta� (Voxelotor) 440-4R2, Global Blood Therapeutics., 4/28/2023 - 12/31/2024, Obligated Amount: $163080; Anticipated Amount: $163080
Sickle Treatment and Outcomes Research in the Midwest (STORM), Cincinnati Childrens Hospital Medical Center., 9/1/2021 - 8/31/2026, Obligated Amount: $348000; Anticipated Amount: $348000
Platelet Decline as a Predictor of Complications in Sickle Cell Disease Sickle cell disease, Takeda Pharmaceuticals., 3/3/2021 - 8/31/2022, Obligated Amount: $216729.81; Anticipated Amount: $216729.81
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients with Sickle Cell Disease or Other Anemias, ApoPharma., 12/12/2014 - 10/1/2015, No Obligated Amount Set; No Anticipated Amount Set
Selected Publications
Han, Jin, Zhang, Xu, Molokie, Robert E, Njoku, Franklin U, Ivy, Zalaya K, Farooqui, Marwah, Gordon, Tara, Williams, Anthony, Gordeuk, Victor R, Saraf, Santosh L. (2026). Impact of voxelotor discontinuation on patients with sickle cell disease. British Journal of Haematology. doi:10.1111/bjh.70567.
Zhang, Xu, Shah, Binal N, Han, Jin, Nouraie, Mehdi, Zhang, Yingze, Machado, Roberto F, Gladwin, Mark T, Saraf, Santosh L, Gordeuk, Victor R. (2026). Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease. British Journal of Haematology, 10.1111/bjh.70517. doi:10.1111/bjh.70517.
Han, Jin, Saraf, Santosh, Gorduek, Victor. (2026). Sickle Cell Disease. Dipiro’s Pharmacotherapy: A Pathophysiologic Approach, 13th Edition. McGraw Hill / Medical.
Bartolucci, Pablo, Audureau, Étienne, Audard, Vincent, Galactéros, Frédéric, Lettre, Guillaume, Anthony, Charmaine, Egbujo, Olufolake, Han, Jin, Ruiz, Maria Armila, Lash, James P, Gordeuk, Victor R, Zhang, Xu, Saraf, Santosh L. (2026). Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia. American Journal of Hematology, 101, (2), 304-310. doi:10.1002/ajh.70155.
Sun, Ryan, Srivastava, Anand, Zapater, Joseph L, Njoku, Franklin, Han, Jin, Ivy, Zalaya, Farooqui, Marwah, Rizvi, Insia, Layden, Brian, Molokie, Robert E, Gordeuk, Victor R, Saraf, Santosh L. (2025). Diabetes mellitus and APOL1 genotype increase the risk for chronic kidney disease progression in sickle cell disease. Blood, 145, (24), 2927-2930. doi:10.1182/blood.2024027839.
Zhang, Xu, Shah, Binal N, Han, Jin, López, José A, Chung, Dominic W, Chen, Junmei, Saraf, Santosh L, Gordeuk, Victor R. (2025). Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes. American Journal of Hematology, 100, (5), 913-916. doi:10.1002/ajh.27636.
Sun, Ryan, Srivastava, Anand, Derebail, Vimal K, Han, Jin, Molokie, Robert E, Gordeuk, Victor, Saraf, Santosh L. (2024). GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease. American Journal of Hematology, 99, (8), 1610-1612. doi:10.1002/ajh.27348.
Han, Jin, Zhang, Xu, Shah, Binal N, Saraf, Santosh L, Gordeuk, Victor R. (2024). Alkaline phosphatase as a marker for painful vaso‐occlusive events and other acute complications in sickle cell disease. British Journal of Haematology, 205, (2), 716-718. doi:10.1111/bjh.19554.
Park, Joshua J, Cabel, Gervacio Y, Cheng, Kevin K, Dang, Jefferson, Ardati, Amer K, Han, Jin, Lee, James C. (2024). Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention. Pharmacogenomics, 25, (7), 293-298. doi:10.1080/14622416.2024.2355862.
Professional Leadership
ACCP AmCare PRN Research Process Committee, 1/1/2026 - Present
ACCP 2026 Annual Meeting Program Committee, 10/1/2024 - Present
Taiwan Society of Health-System Pharmacists Ambulatory Care Board Certification Committee, 7/1/2022 - Present
ACCP 2023 Annual Meeting Program Committee, 10/15/2021 - 10/15/2023
Notable Honors
2022, Fellowship in the American College of Clinical Pharmacy (FCCP), the American College of Clinical Pharmacy (ACCP)
Education
Degrees:
PharmD, University of Illinois at Chicago, United States
Postgraduate Training:
PGY1 Pharmacy Resident, Rush University Medical Center, United States
Licensures and Certifications
Registered Pharmacist, State of Illinois, Date Not Set - Present
Pharmacotherapy Specialist, Board of Pharmacy Specialties, Date Not Set - Present